Acyclovir Lauriad®
Phase I (BA 2004/21/01) Pharmacokinetic Study,
healthy volunteers (Completed)
Conducted at a single centre in France, this pharmacokinetic
study of acyclovir Lauriad® in healthy volunteers was designed
to evaluate the pharmacokinetic parameters of acyclovir in plasma,
saliva and lips after a single administration of the acyclovir
Lauriad® 50mg and 100mg mucodhesive buccal tablets, compared
to a reference treatment (Zovirax 200mg tablet). General and
local tolerance of acyclovir Lauriad® has also been evaluated
in this randomised, crossover trial on 12 healthy men and women.
A prompt and lasting elevated concentration was obtained
for 24 hours in the saliva, corresponding to a continuous
presence of the active pharmaceutical ingredient. A very elevated
concentration above minimum effective concentration (MIC)
levels was also found at the labial site for 24 hours.
|
